GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (NAS:QNTM) » Definitions » Enterprise Value

QNTM (Quantum BioPharma) Enterprise Value : $1.38 Mil (As of Mar. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quantum BioPharma's Enterprise Value is $1.38 Mil. Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-11.08 Mil. Therefore, Quantum BioPharma's EV-to-EBIT ratio for today is -0.12.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Quantum BioPharma's Enterprise Value is $1.38 Mil. Quantum BioPharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-10.58 Mil. Therefore, Quantum BioPharma's EV-to-EBITDA ratio for today is -0.13.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Quantum BioPharma's Enterprise Value is $1.38 Mil. Quantum BioPharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil. Therefore, Quantum BioPharma's EV-to-Revenue ratio for today is .

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Quantum BioPharma's Enterprise Value is $1.38 Mil. Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.89 Mil. Therefore, Quantum BioPharma's EV-to-FCF ratio for today is -0.20.


Quantum BioPharma Enterprise Value Historical Data

The historical data trend for Quantum BioPharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma Enterprise Value Chart

Quantum BioPharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only 38.67 12.90 6.38 13.85 32.73

Quantum BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.58 32.73 26.95 4.22 0.28

Competitive Comparison of Quantum BioPharma's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum BioPharma's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's Enterprise Value falls into.



Quantum BioPharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Quantum BioPharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Quantum BioPharma's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma  (NAS:QNTM) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Quantum BioPharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.382/-11.08
=-0.12

Quantum BioPharma's current Enterprise Value is $1.38 Mil.
Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.08 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Quantum BioPharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1.382/-10.579
=-0.13

Quantum BioPharma's current Enterprise Value is $1.38 Mil.
Quantum BioPharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.58 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Quantum BioPharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1.382/0
=

Quantum BioPharma's current Enterprise Value is $1.38 Mil.
Quantum BioPharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Quantum BioPharma's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.382/-6.892
=-0.20

Quantum BioPharma's current Enterprise Value is $1.38 Mil.
Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum BioPharma Business Description

Traded in Other Exchanges
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.